Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: Therapeutic implications

Blood

Volumn 99, Issue 12, 2002, Pages 4525-4530

  Mitsiades, Nicholas ^a,b   Mitsiades, Constantine S ^a,b   Poulaki, Vassiliki ^a,b   Chauhan, Dharminder ^a,b   Richardson, Paul G ^a,b   Hideshima, Teru ^a,b   Munshi, Nikhil C ^a,b   Treon, Steven P ^a,b   Anderson, Kenneth C ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CASPASE 8; DEXAMETHASONE; FAS ANTIGEN; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; SOMATOMEDIN C; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOMODULATION; MULTIPLE MYELOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0037097595     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.12.4525     Document Type: Article

References (35)

1. Antitumor activity of thalidomide in refractory multiple myeloma
2. Thalidomide in multiple myeloma
3. Thalidomide is an inhibitor of angiogenesis
4. Thatidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
5. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic applications
6. Immunomodulatory denvatives (IMiDs) of thalidomide (Thal) inhibit the proliferation of multiple myeloma (MM) cell lines and block VEGF-induced activation of the MAPK-pathway
7. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
8. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha
9. A phase 1 study of oral CC5013, an immunomodulatory thalidomide (Thai) derivative, in patients with relapsed and refractory multiple myeloma (MM)
10. Hypofhesis: Thalidomide embryopathy-proposed mechanism of action
11. Mechanism of action in thalidomide teratogenesis
12. Effects of thalidomide and related melabolites in a mouse comeal model of neovascularization
13. High plasma basic fibroblost growth factor concentration is associated with response to thalidomide in progressive multiple myeloma
14. Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines
15. IGF-1-induced activation of NF-kB and upregulation of intracellular anti-apoptotic proteins in human multiple myeloma cells: Therapeutic implications
16. Insulin-like growth factor I is a dual effector of multiple myeloma call growth
17. Cytokines prevent dexamethasone-induced apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in a new multiple myeloma cell line
18. Mutiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors
19. Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved Into a soluble form by a metalloproteinase
20. Modulation of JunD.AP-1 DNA binding activity by AP-1-associated factor 1 (AF-1)
21. Thalidomide: The revival of a drug with therapeutic promise in the treatment of cancer
22. Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma cells
23. Apaptosis signaling by death receptors
24. Apoptosis induced by FasL and TRAIL/Apo2L in the pathogenesis of thyroid diseases
25. Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells
26. NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling
27. Inhibition of NF-kappa B activity by thalidomide through suppression of Ikappa B kinase activity
28. Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2
29. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells
30. Thalidomide for resistant and relapsing myeloma
31. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: Therapeutic applications
32. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control
33. NF-kappaB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and C-IAP2 to suppress caspase-8 activation
34. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: Therapeutic applications
35. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma